• SAB Biotherapeutics flagged encore Phase 1 results for SAB-142 in Stage 3 type 1 diabetes for presentation at CRC 2026.
• Data will be presented Oct. 10 in Philadelphia, with a focus on safety, early efficacy signals, and mechanism-of-action findings.
• The company positioned SAB-142 as a potentially disease-modifying, redosable immunotherapy intended to preserve endogenous insulin production.
• Updates will also cover the SAFEGUARD and PRISE-hATG studies evaluating SAB-142 across the type 1 diabetes disease continuum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010830PRIMZONEFULLFEED9836279) on October 01, 2026, and is solely responsible for the information contained therein.